Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120801

Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.

Scandinavian journal of rheumatology 20120801

Monitoring of bone turnover markers does not improve persistence with ibandronate treatment.

Joint, bone, spine : revue du rhumatisme 20120701

Bisphosphonate-related osteonecrosis of the mandible secondary to postural pressure.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120701

Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.

Arthritis care & research 20120701

Once-monthly oral ibandronate treatment in an adolescent with recurrent fractures and inadequately low bone mass.

Journal of paediatrics and child health 20120701

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120601

Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120601

Gastrointestinal bleeding following intravenous ibandronate administration.

Journal of pharmacy practice 20120601

Monthly ibandronate for the prevention of bone loss in patients after liver transplantation.

Transplantation proceedings 20120601

Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20120514

[Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection].

Se pu = Chinese journal of chromatography 20120401

Effect of dosing interval duration of intermittent ibandronate treatment on the healing process of femoral osteotomy in a rat fracture model.

Calcified tissue international 20120301

Phase I clinical study to select a novel oral formulation for ibandronate containing the excipient sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC).

Die Pharmazie 20120301

Question: In postmenopausal women with osteoporosis is once monthly oral ibandronate (150 mg) therapy preferred to once weekly oral bisphosphonate therapy.

The Journal of the Oklahoma State Medical Association 20120301

Ibandronate and calcitriol reduces fracture risk, reverses bone loss, and normalizes bone turnover after LTX.

Transplantation 20120215

Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro.

Clinical oral investigations 20120201

Counting touching cell nuclei using fast ellipse detection to assess in vitro cell characteristics: a feasibility study.

Clinical oral investigations 20120201

The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.

Clinical oral investigations 20120201

Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120201

[Pelvic pain in the athlete: not always that simple...].

Revue medicale suisse 20120125

Effect of monthly ibandronate on hip structural geometry in men with low bone density.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120101

Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.

Bone 20120101

Possible role of oral ibandronate administration in Osteonecrosis of the Jaw: a case report.

International journal of immunopathology and pharmacology 20120101

Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate.

Onkologie 20120101

Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain.

Onkologie 20120101

Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study.

American journal of nephrology 20120101

Bisphosphonates for osteoporosis in primary biliary cirrhosis.

The Cochrane database of systematic reviews 20111207

Daily or monthly ibandronate prevents or restores deteriorations of bone mass, architecture, biomechanical properties and markers of bone turnover in androgen-deficient aged rats.

The aging male : the official journal of the International Society for the Study of the Aging Male 20111201

Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner--a quantitative in vitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2.

Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20111201

Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial.

Breast (Edinburgh, Scotland) 20111201

Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study.

Bone 20111201

Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia.

Clinical rheumatology 20111201

Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women.

Biopharmaceutics & drug disposition 20111101

The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancer.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20111001

Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.

Journal of managed care pharmacy : JMCP 20111001

Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study.

Anticancer research 20111001

Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta.

Chinese medical journal 20111001

Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis.

American journal of therapeutics 20110901

A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.

American journal of therapeutics 20110901

Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials.

The Korean journal of internal medicine 20110901

Administration of sodium ibandronate in the treatment of complicated giant cell tumor of the spine.

Spine 20110801

Non-surgical management of stage 3 biphosphonate-related oroantral fistula.

The British journal of oral & maxillofacial surgery 20110701

Effect of bisphosphonates on anodized and heat-treated titanium surfaces: an animal experimental study.

Journal of periodontology 20110701

[Assessment of volumetric bone mineral density and geometry for hip with clinical CT device].

Clinical calcium 20110701

Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.

International journal of clinical oncology 20110601

Intravenous bisphosphonates for post-menopausal osteoporosis: adherence to a network guideline.

Journal of clinical pharmacy and therapeutics 20110601

Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis.

Journal of gastrointestinal and liver diseases : JGLD 20110601

Commentary on an article by Jacob S. Vandermeer et al.: 'Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head. A combined therapy that stimulates bone formation and decreases femoral head deformity'.

The Journal of bone and joint surgery. American volume 20110518

Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head: a combined therapy that stimulates bone formation and decreases femoral head deformity.

The Journal of bone and joint surgery. American volume 20110518

Ibandronate does not reduce the anabolic effects of PTH in ovariectomized rat tibiae: a microarchitectural and mechanical study.

Bone 20110501

Low-magnitude high-frequency vibration (LMHFV) enhances bone remodeling in osteoporotic rat femoral fracture healing.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20110501

Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110301

Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro.

Oral diseases 20110301

Bone mineral disease in children after renal transplantation in steroid-free and steroid-treated patients--a prospective study.

Pediatric transplantation 20110301

Treatment of lumbar pars interarticularis stress injuries in athletes with intravenous bisphosphonates: five case studies.

Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine 20110301

The treatment of symptomatic osteoporotic spinal compression fractures.

The Journal of the American Academy of Orthopaedic Surgeons 20110301

Stability indicating ion chromatography method for the simultaneous determination of ibandronate sodium drug substance and its impurities.

Journal of pharmaceutical and biomedical analysis 20110220

Osteonecrosis of the jaw and the role of macrophages.

Journal of the National Cancer Institute 20110202

Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro.

Clinical oral investigations 20110201

Bisphosphonates inhibit phosphorylation of signal transducer and activator of transcription 3 and expression of suppressor of cytokine signaling 3: implications for their effects on innate immune function and osteoclastogenesis.

Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20110201

Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D.

World journal of gastroenterology 20110121

Ibandronate promotes osteogenic differentiation of periodontal ligament stem cells by regulating the expression of microRNAs.

Biochemical and biophysical research communications 20110107

Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines.

Acta oncologica (Stockholm, Sweden) 20110101

Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function.

Pediatric nephrology (Berlin, Germany) 20110101

[Ibandronate].

Clinical calcium 20110101

When do bisphosphonates make the most sense?

The Journal of family practice 20110101

The role of i.v. ibandronate administration in osteoporosis therapy.

Endokrynologia Polska 20110101

Adverse cutaneous drug reactions to ibandronate.

European journal of dermatology : EJD 20110101

[The role of i.v. ibandronate administration in osteoporosis therapy].

Endokrynologia Polska 20110101

[Osteonecrosis of the jaw associated with oral treatment with ibandronate].

Anales del sistema sanitario de Navarra 20110101

Drug-drug interaction study between a novel oral ibandronate formulation and metformin.

Arzneimittel-Forschung 20110101

Prospective clinical study of once monthly ibandronate in the treatment of osteoporosis and prevention of fractures in postmenopausal women: ORPHEUM Study.

Srpski arhiv za celokupno lekarstvo 20110101

Adherence to bisphosphonate therapy in postmenopausal osteoporotic women.

Folia medica 20110101

Preparation and properties of new co-crystals of ibandronate with gluco- or galactopyranoside derivatives.

Molecules (Basel, Switzerland) 20101208

Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.

Clinical breast cancer 20101201

Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20101101

Bilateral simultaneous femoral diaphyseal fractures in a patient with long-term ibandronate use.

Orthopedics 20101011

Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20101001

Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)--assessment of corresponding epitopes.

Clinical biochemistry 20101001

Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate.

Calcified tissue international 20101001

The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate.

Journal of cellular biochemistry 20100901

Successful treatment of SAPHO syndrome with ibandronate.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20100801

Treatment of osteoporosis after liver transplantation with ibandronate.

Transplant international : official journal of the European Society for Organ Transplantation 20100701

Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100601

Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.

Bone 20100601

Postmenopausal osteoporosis: another approach to management.

The Journal of family practice 20100601

[Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy].

Ginecologia y obstetricia de Mexico 20100601

An in vitro assay to measure targeted drug delivery to bone mineral.

ChemMedChem 20100503

Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.

Journal of bone and mineral metabolism 20100501

Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials.

International journal of clinical practice 20100501

How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.

Journal of the American Dental Association (1939) 20100501

Efficacy and safety of monthly ibandronate in men with low bone density.

Bone 20100401

Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs).

Bioorganic & medicinal chemistry 20100401

Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study.

Bone 20100301

Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA.

Current medical research and opinion 20100301

Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.

Journal of medical economics 20100301

Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20100201

Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature.

Journal of chemotherapy (Florence, Italy) 20100201

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100101

Management of symptomatic bone metastases from breast cancer with concomitant use of external radiotherapy and ibandronate: results of a prospective, pilot study.

The breast journal 20100101

The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20100101

Efficacy and safety of once monthly ibandronate treatment in patients with reduced bone mineral density--ESTHER study.

Srpski arhiv za celokupno lekarstvo 20100101

Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.

Journal of cancer research and therapeutics 20100101

Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption--implications for osteoclast quality.

BMC musculoskeletal disorders 20100101

Challenges in clinical patient management.

Cancer investigation 20100101

Long-term renal safety profile of ibandronate 6 mg infused over 15 minutes.

Onkologie 20100101

Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates.

Endocrine research 20100101

Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid.

Arthritis research & therapy 20100101

Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease--a pilot retrospective study.

Cardiology 20100101

The efficiency of Bonviva (Ibadronate) in women with pre-post menopause.

Medicinski arhiv 20100101

Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates.

Prilozi 20100101

Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells.

The Journal of international medical research 20100101

Metronomic administration of ibandronate and its anti-angiogenic effects in vitro.

Microvascular research 20091201

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.

Current medical research and opinion 20091201

Review of osteoporosis pharmacotherapy for geriatric patients.

The American journal of geriatric pharmacotherapy 20091201

Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091110

Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer.

European journal of cancer care 20091101

Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.

Calcified tissue international 20091101

A retrospective clinical and radiographic study on healing of periradicular lesions in patients taking oral bisphosphonates.

Journal of endodontics 20091101

High-throughput HPLC-MS/MS method to determine ibandronate in human plasma for pharmacokinetic applications.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091001

[Anti-fracture efficacy of intravenous ibandronate: how to translate epidemiological studies into daily clinical practice].

Revue medicale de Liege 20091001

Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090901

Ibandronate reduces endogenous reactive oxygen species levels in cultured prostate cancer and endothelial cells.

Microvascular research 20090901

Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy.

Women's health (London, England) 20090901

Tolerability of dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease: a case series.

Onkologie 20090901

[Emergencies in hematology and oncology].

Deutsche medizinische Wochenschrift (1946) 20090901

[Diagnosis and treatment of bone marrow edema syndrome of the hip and differential diagnosis from avascular necrosis of femoral head].

Zhongguo gu shang = China journal of orthopaedics and traumatology 20090901

Safety and antisorptive power of Ibandronate applied in the real-life setting.

Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20090901

Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women.

International journal of rheumatic diseases 20090901

Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.

Current medical research and opinion 20090801

Pricey osteoporosis remedy doesn't beat older drugs.

Consumer reports 20090801

Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20090701

Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.

Journal of women's health (2002) 20090701

Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.

Clinical therapeutics 20090701

Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20090601

Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.

Bone 20090501

Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.

Southern medical journal 20090501

[Drugs under development for osteoporosis ].

Nihon rinsho. Japanese journal of clinical medicine 20090501

Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.

The Annals of pharmacotherapy 20090401

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Clinical therapeutics 20090401

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.

Bone 20090301

Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study.

Clinical rheumatology 20090301

Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis.

Bone 20090301

The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats.

Biomaterials 20090301

Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090201

Plain film and CBCT findings in a case of bisphosphonate-related osteonecrosis of the jaw.

Quintessence international (Berlin, Germany : 1985) 20090201

Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.

The American journal of medicine 20090201

Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.

Cancer investigation 20090201

Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.

The Journal of clinical endocrinology and metabolism 20090101

Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20090101

[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].

Clinical calcium 20090101

Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.

Genome biology 20090101

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment.

Clinical interventions in aging 20090101

Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?

Acta oncologica (Stockholm, Sweden) 20090101

Dendritic multishell architectures for drug and dye transport.

Journal of controlled release : official journal of the Controlled Release Society 20081218

Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease.

Journal of cancer research and clinical oncology 20081201

Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates.

Journal of surgical oncology 20081201

Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update.

Expert opinion on pharmacotherapy 20081201

[Bisphosphonates for osseus invasion caused by bronchial carcinoma].

Deutsche medizinische Wochenschrift (1946) 20081101

Ibandronate: is there an effect on nonvertebral fractures?

Clinical rheumatology 20081001

An open-label pilot trial of ibandronate for complex regional pain syndrome.

The Clinical journal of pain 20081001

Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20081001

[Ibandronate in the treatment of postmenopausal osteoporosis].

Lege artis medicinae : uj magyar orvosi hirmondo 20081001

Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.

Journal of pain and symptom management 20080901

Acute phase reaction with intravenous ibandronate.

The American journal of medicine 20080901

Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.

Current osteoporosis reports 20080901

Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.

The American journal of managed care 20080901

[Update on treatment of postmenopausal osteoporosis].

Revue medicale de Bruxelles 20080901

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.

Clinical rheumatology 20080801

[Daily practice using the guidelines for prevention and treatment of osteoporosis. Evolution of bisphosphonate therapy. Intravenous injection].

Clinical calcium 20080801

Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study.

Annals of oncology : official journal of the European Society for Medical Oncology 20080701

Identification of novel bone-specific molecular targets of binge alcohol and ibandronate by transcriptome analysis.

Alcoholism, clinical and experimental research 20080701

Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications.

Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20080701

Ibandronate in profile: drug characteristics and clinical efficacy.

Expert opinion on drug metabolism & toxicology 20080701

Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety.

Toxicology in vitro : an international journal published in association with BIBRA 20080601

Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.

Postgraduate medical journal 20080601

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II).

Joint, bone, spine : revue du rhumatisme 20080501

Ibandronate in benign bone disease.

Reviews on recent clinical trials 20080501

Quarterly intravenous ibandronate for postmenopausal osteoporosis.

Women's health (London, England) 20080501

Effects of the bisphosphonate ibandronate on hyperalgesia, substance P, and cytokine levels in a rat model of persistent inflammatory pain.

European journal of pain (London, England) 20080401

Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.

Clinical therapeutics 20080401

A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.

Breast cancer research and treatment 20080301

Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080301

Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands.

Current medical research and opinion 20080301

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.

The Journal of rheumatology 20080301

[Osteonecrosis of the jaw developing during bisphosphonate treatment].

Magyar onkologia 20080301

Reply to the article 'oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases' by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171).

Annals of oncology : official journal of the European Society for Medical Oncology 20080201

[Prescription of bisphosphonates in prostate cancer].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080201

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.

Current medical research and opinion 20080101

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies.

Current medical research and opinion 20080101

Vertebral fracture diagnosis in the multinational BONE study of oral ibandronate: quality management in radiology.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20080101

Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.

Breast cancer research : BCR 20080101

Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.

PharmacoEconomics 20080101

Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model.

PharmacoEconomics 20080101

[Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].

Recenti progressi in medicina 20080101

Rapid suppression of bone resorption marker levels with ibandronate therapy in a bisphosphonate-naïve population.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20080101

Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients.

The Journal of international medical research 20080101

Renal toxicity following zoledronic acid reversed with ibandronate in a prostate cancer patient with bone metastases.

Urologia internationalis 20080101

Ibandronate uptake in the jaw is similar to long bones and vertebrae in the rat.

Journal of bone and mineral metabolism 20080101

Treatment of reduced bone density with ibandronate in dialysis patients.

Journal of nephrology 20080101

Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.

Current clinical pharmacology 20080101

Osteonecrosis of the jaw in a patient treated with ibandronate.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology 20080101

[Hypercalcaemic crisis and acute renal failure due to primary hyperparathyroidism].

Deutsche medizinische Wochenschrift (1946) 20080101

Ibandronate: a review of its use in the management of postmenopausal osteoporosis.

Drugs 20080101

Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review.

Clinical and experimental rheumatology 20080101

Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.

Journal of cutaneous pathology 20071201

Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.

Minerva endocrinologica 20071201

Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients.

Acta orthopaedica 20071201

Linköping University Medical Dissertation No. 1033. Following the mevalonate pathway to bone heal alley.

Acta orthopaedica. Supplementum 20071201

[New bone density conservation agents for osteoporosis under research and development: Ibandronate].

Nihon rinsho. Japanese journal of clinical medicine 20071128

Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.

European journal of cancer care 20071101

Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates.

Annals of the New York Academy of Sciences 20071101

Vitamin D and ibandronate prevent cancellous bone loss associated with binge alcohol treatment in male rats.

Bone 20071001

Osteoporosis: non-hormonal treatment.

Climacteric : the journal of the International Menopause Society 20071001

[The benefit from ibandronate in the treatment of postmenopausal osteoporosis].

Vnitrni lekarstvi 20071001

Application of metabonomics in a comparative profiling study reveals N-acetylfelinine excretion as a biomarker for inhibition of the farnesyl pathway by bisphosphonates.

Chemical research in toxicology 20070901

Osteoporosis medication profile preference: results from the PREFER-US study.

Health expectations : an international journal of public participation in health care and health policy 20070901

[Adjuvant therapy of locally advanced prostate carcinoma with ibandronate].

Der Urologe. Ausg. A 20070901

Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or without impaired renal function.

Journal of clinical pharmacology 20070801

Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.

British dental journal 20070728

Changes in bone remodelling and antifracture efficacy of intermittent bisphosphonate therapy: implications from clinical studies with ibandronate.

Annals of the rheumatic diseases 20070701

Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.

Annals of oncology : official journal of the European Society for Medical Oncology 20070701

New and emerging treatments for osteoporosis.

Current opinion in rheumatology 20070701

Pharmacological treatment of osteoporosis for people over 70.

Aging clinical and experimental research 20070601

Validation of a capillary electrophoresis method for the analysis of ibandronate related impurities.

Journal of pharmaceutical and biomedical analysis 20070509

Bisphosphonates. A cornerstone of osteoporosis treatment.

Mayo Clinic women's healthsource 20070501

[Nurse's role in the home management of patients with breast cancer and bone metastases].

Soins; la revue de reference infirmiere 20070501

Ibandronate treatment reverses glucocorticoid-induced loss of bone mineral density and strength in minipigs.

Bone 20070301

Use of intravenous bisphosphonates in osteoporosis.

Current osteoporosis reports 20070301

Prevention and treatment of glucocorticoid-induced osteoporosis.

Current osteoporosis reports 20070301

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women.

Clinical interventions in aging 20070301

Differential effects of bisphosphonates on breast cancer cell lines.

Cancer letters 20070208

Effects of ibandronate on bone quality: preclinical studies.

Bone 20070201

Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.

Bone 20070201

Drug approvals.

The Nurse practitioner 20070201

Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment.

International journal of radiation oncology, biology, physics 20070101

Retention, distribution, and effects of intraosseously administered ibandronate in the infarcted femoral head.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20070101

[Therapeutic agents for disorders of bone and calcium metabolism: Ibandronate].

Clinical calcium 20070101

The bisphosphonate ibandronate accelerates osseointegration of hydroxyapatite-coated cementless implants in an animal model.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20070101

Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis.

Journal of bone and mineral metabolism 20070101

Clinical usefulness of bisphosphonates in oncology: treatment of bone metastases, antitumoral activity and effect on bone resorption markers.

The International journal of biological markers 20070101

A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate.

Clinical & experimental metastasis 20070101

Safety considerations with bisphosphonates for the treatment of osteoporosis.

Drug safety 20070101

A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover.

Clinical and experimental rheumatology 20070101

[Does ibandronate (Bonviva) have an impact on non-vertebral fractures?].

Reumatizam 20070101

Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.

International journal of clinical pharmacology and therapeutics 20061201

Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.

Current medical research and opinion 20061201

Bisphosphonates.

Annals of the New York Academy of Sciences 20061201

Compliance with treatment for osteoporosis.

Lancet (London, England) 20061111

Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate.

Kidney international 20061101

Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels?

Kidney international 20061101

[Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis].

Revue medicale de Liege 20061101

Ibandronate (boniva) offers new options for osteoporosis.

The Nurse practitioner 20061001

Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis.

Current drug metabolism 20061001

Parathyromatosis and the challenge of treatment.

American journal of kidney diseases : the official journal of the National Kidney Foundation 20060901

[DVO guideline 2006. What changes have there been in the diagnosis, prevention and treatment of osteoporosis?].

Zeitschrift fur Rheumatologie 20060901

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.

International journal of clinical practice 20060801

Rinsing morcellised bone grafts with bisphosphonate solution prevents their resorption. A prospective randomised double-blinded study.

The Journal of bone and joint surgery. British volume 20060801

New drugs 06, part II.

Nursing 20060801

Intravenous ibandronate (Boniva).

The Medical letter on drugs and therapeutics 20060801

Local bioavailability and distribution of systemically (parenterally) administered ibandronate in the infarcted femoral head.

Bone 20060701

Bone marker response in chronic diffuse sclerosing osteomyelitis treated with intravenous ibandronate.

Annals of the rheumatic diseases 20060701

Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results.

European journal of cancer care 20060701

Osseointegration of cementless implants with different bisphosphonate regimens.

Clinical orthopaedics and related research 20060601

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.

Arthritis and rheumatism 20060601

Less frequent dosing of bisphosphonates in osteoporosis: focus on ibandronate.

Current medical research and opinion 20060601

Fracture prevention in postmenopausal women.

Clinical evidence 20060601

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.

Annals of the rheumatic diseases 20060501

Extracellular matrix changes in knee joint cartilage following bone-active drug treatment.

Cell and tissue research 20060501

Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.

Pharmacotherapy 20060501

What's new in clinical pharmacology and therapeutics.

WMJ : official publication of the State Medical Society of Wisconsin 20060501

Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.

Maturitas 20060420

Adherence, patient preference and dosing frequency: understanding the relationship.

Bone 20060401

Beyond daily dosing: clinical experience.

Bone 20060401

Ibandronate: pharmacology and preclinical studies.

Bone 20060401

Once-monthly dosing: an effective step forward.

Bone 20060401

Preventing osteoporosis-related fractures: an overview.

The American journal of medicine 20060401

Injectable drug approved for osteoporosis.

Health news (Waltham, Mass.) 20060401

Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.

Clinical therapeutics 20060401

Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans.

Annals of the New York Academy of Sciences 20060401

Drug insight: Bisphosphonates for postmenopausal osteoporosis.

Nature clinical practice. Endocrinology & metabolism 20060401

Enthalpy versus entropy-driven binding of bisphosphonates to farnesyl diphosphate synthase.

Journal of the American Chemical Society 20060322

[Therapy of hypercalcemia with ibandronate in case of acute renal failure].

Der Internist 20060301

Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.

Current osteoporosis reports 20060301

A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20060201

Independent pathways in the modulation of osteoclastic resorption by intermediates of the mevalonate biosynthetic pathway: the role of the retinoic acid receptor.

Bone 20060201

Strategies for the prevention and treatment of osteoporosis during early postmenopause.

American journal of obstetrics and gynecology 20060201

Rapid pain relief and remission of sternocostoclavicular hyperostosis after intravenous ibandronate therapy.

Journal of bone and mineral metabolism 20060101

Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.

Breast cancer research : BCR 20060101

[Ibandronate once a month].

Medizinische Monatsschrift fur Pharmazeuten 20060101

Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer.

Drugs 20060101

Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosis.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20060101

Rapid infusion of ibandronate in lung cancer patients with bone metastases.

Anticancer research 20060101

Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate.

Drugs 20060101

Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines.

Clinical & experimental metastasis 20060101

Intravenous ibandronate: in the treatment of osteoporosis.

Drugs 20060101

Ibandronate: its role in metastatic breast cancer.

The oncologist 20060101

Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports.

Acta haematologica 20060101

Non-ulcerating calcific uremic arteriolopathy skin lesion treated successfully with intravenous ibandronate.

Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 20060101

Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.

Drug safety 20060101

Intravenous ibandronate in the treatment of osteoporosis: profile report.

Drugs & aging 20060101

Safety of oral ibandronate in the treatment of bone metastases from breast cancer : long-term follow-up experience.

Clinical drug investigation 20060101

Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial.

Clinical drug investigation 20060101

[The role of ibandronate in the daily oncological practice].

Magyar onkologia 20060101

[Ibandronate].

Reumatizam 20060101

Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20051201

Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20051201

Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?

Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery 20051201

Newer drug treatments: their effects on fracture prevention.

Best practice & research. Clinical rheumatology 20051201

Acute renal effects of intravenous bisphosphonates in the rat.

Basic & clinical pharmacology & toxicology 20051201

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).

Current medical research and opinion 20051201

Highlights From ECCO 13-The European Cancer Conference Paris, France October 30 to November 3, 2005.

Clinical breast cancer 20051201

Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.

Bone 20051101

High dosage treatment of nitrogen-containing bisphosphonate ibandronate is required for osseointegration of cementless metal implants.

Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20051101

S0307. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer.

Clinical advances in hematology & oncology : H&O 20051101

Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis.

Bone 20051001

Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age.

The Journal of rheumatology 20051001

Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis.

Expert opinion on pharmacotherapy 20051001

Review of treatment modalities for postmenopausal osteoporosis.

Southern medical journal 20051001

Ibandronate: efficacy in the treatment of metastatic bone disease.

Future oncology (London, England) 20051001

Analytical methods for the quantification of ibandronate in body fluids and bone.

Journal of pharmaceutical and biomedical analysis 20050901

Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.

The Journal of clinical endocrinology and metabolism 20050901

The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats.

Bone 20050801

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20050801

Ibandronate (Boniva): a new oral bisphosphonate.

Obstetrics and gynecology 20050801

Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.

Clinical therapeutics 20050801

A new option for osteoporosis.

The Johns Hopkins medical letter health after 50 20050701

New therapeutic agents for the treatment of bone diseases.

Expert opinion on biological therapy 20050601

Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.

Clinical breast cancer 20050601

First once-a-month osteoporosis pill approved.

Harvard women's health watch 20050601

A bright future for osteoporosis treatment.

Drug news & perspectives 20050601

Longer-lasting osteoporosis drugs sought.

JAMA 20050525

Bisphosphonates in breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology 20050501

Changes in bone structure after augmentation cystoplasty in chronic uraemic rats.

BJU international 20050501

The issue of renal safety of zoledronic acid from a nephrologist's point of view.

The oncologist 20050501

'Safety and convenience of a 15-minute infusion of zoledronic acid': not so safe.

The oncologist 20050501

New drugs and dosage forms.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20050501

Ibandronate (Boniva): a new oral bisphosphonate.

The Medical letter on drugs and therapeutics 20050425

Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.

Annals of oncology : official journal of the European Society for Medical Oncology 20050301

Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs.

The Journal of bone and joint surgery. American volume 20050301

Oral antiresorptive therapy.

Current rheumatology reports 20050301

Rapid prevention of vertebral fractures associated with osteoporosis.

Orthopedics 20050301

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.

Current medical research and opinion 20050301

Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20050201

Explicit solutions for a class of indirect pharmacodynamic response models.

Computer methods and programs in biomedicine 20050201

Ibandronate in metastatic bone disease: a review of preclinical data.

Anti-cancer drugs 20050201

Oral ibandronic acid.

IDrugs : the investigational drugs journal 20050201

[Ibandronate as a new therapeutic agent for osteoporosis].

Clinical calcium 20050101

The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.

Oncology 20050101

Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.

Treatments in endocrinology 20050101

[Monthly tablet].

Krankenpflege Journal 20050101

New drugs: entecavir, ibandronate sodium, and pegaptanib sodium.

Journal of the American Pharmacists Association : JAPhA 20050101

Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.

Treatments in endocrinology 20050101

Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients.

Anticancer research 20050101

[Postmenopausal osteoporosis].

Krankenpflege Journal 20050101

Efficacy of ibandronate in metastatic bone disease: review of clinical data.

The oncologist 20050101

Renal safety of ibandronate.

The oncologist 20050101

Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.

Current pharmaceutical design 20050101

Once-monthly ibandronate.

Treatments in endocrinology 20050101

High bone-binding capacity of ibandronate in hemodialysis patients.

International journal of clinical pharmacology research 20050101

[Zoledronic acid and bone pathology in the course of neoplasia. Part I].

Tumori 20050101

[Monthly tablet in postmenopausal osteoporosis].

Krankenpflege Journal 20050101

Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20041201

A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.

British journal of clinical pharmacology 20041201

Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.

Expert review of anticancer therapy 20041201

Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.

Seminars in oncology 20041201

[Clinical trial on ibandronate in patients with tumor-associated hypercalcemia].

Zhonghua zhong liu za zhi [Chinese journal of oncology] 20041201

Review of ibandronate in the treatment of metastatic bone disease: experience from phase III trials.

Clinical therapeutics 20041201

Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20041101

Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.

Oncology reports 20041101

Efficacy and safety of ibandronate in the treatment of neoplastic bone disease.

Expert opinion on pharmacotherapy 20041101

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20041001

Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer.

Pain 20041001

The efficacy and safety of oral ibandronate in the treatment of metastatic bone disease in patients with breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology 20041001

Targeting Breast Cancer with Care. Proceedings of a meeting. Prague, Czech Republic, February 2004.

Seminars in oncology 20041001

Ibandronate reduces skeletal morbidity in patients with breast cancer.

Seminars in oncology 20041001

Ibandronate in metastatic bone pain.

Seminars in oncology 20041001

Managing metastatic bone disease: three case studies.

Seminars in oncology 20041001

The RIB trial.

Clinical oncology (Royal College of Radiologists (Great Britain)) 20041001

Systemic and local ibandronate enhance screw fixation.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society 20040901

Ibandronate: a clinical pharmacological and pharmacokinetic update.

Journal of clinical pharmacology 20040901

Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040901

[Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO].

Der Urologe. Ausg. A 20040901

In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.

Anti-cancer drugs 20040901

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040801

Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone.

Bone 20040701

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.

European journal of cancer (Oxford, England : 1990) 20040701

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20040601

Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells.

International journal of oncology 20040501

Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040501

Ibandronate and prevention of postmenopausal osteoporosis.

Annals of the rheumatic diseases 20040501

Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology 20040501

Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.

Annals of oncology : official journal of the European Society for Medical Oncology 20040501

Efficacy and safety of ibandronate given by intravenous injection once every 3 months.

Bone 20040501

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.

Bone 20040501

[Bone metastases in breast carcinoma. Bisphosphonate protects from complications].

MMW Fortschritte der Medizin 20040401

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies.

British journal of cancer 20040322

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20040301

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

Annals of oncology : official journal of the European Society for Medical Oncology 20040301

Nephrotoxicity of third-generation, intravenous bisphosphonates.

Toxicology 20040301

[Ibandronate].

Nihon rinsho. Japanese journal of clinical medicine 20040201

Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat.

The Journal of biological chemistry 20040116

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040101

Safety and convenience of a 15-minute infusion of zoledronic acid.

The oncologist 20040101

New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate.

Journal of pharmacological and toxicological methods 20040101

[Ibandronate: keep life in motion].

Tumori 20040101

[Oral and parenteral forms of aminobisphosphonate].

Krankenpflege Journal 20040101

[AIOM Conference 2004. Endocrine therapy and management of patients with bone metastasis of breast cancer].

Tumori 20040101

[ESMO Conference 2004. Ibandronate in the treatment of bone metastasis].

Tumori 20040101

Ibandronate improves hyperphosphatemia in dialysis patients with hyperparathyroidism.

International urology and nephrology 20040101

Injectable drug dampens bone loss.

Health news (Waltham, Mass.) 20031201

Is ibandronate effective in multiple myeloma?

European journal of haematology 20031201

Use of highly potent bisphosphonates in the treatment of osteoporosis.

Current osteoporosis reports 20031201

Bisphosphonates in children with bone diseases.

The New England journal of medicine 20031120

Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth.

International journal of cancer 20031110

Ibandronate: new options in the treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998) 20031101

Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.

Annals of the rheumatic diseases 20031001

The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status.

Bone 20031001

Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.

The Journal of clinical endocrinology and metabolism 20031001

Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20031001

The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats.

Toxicology 20030930

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

Annals of oncology : official journal of the European Society for Medical Oncology 20030901

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20030801

Oral weekly ibandronate prevents bone loss in postmenopausal women.

Journal of internal medicine 20030801

Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.

Aging clinical and experimental research 20030801

Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years.

Journal of endocrinological investigation 20030801

The bisphosphonate ibandronate stimulates reverse cholesterol transport out of monocytoid cells by enhanced ABCA1 transcription.

Biochemical and biophysical research communications 20030718

Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20030701

Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate.

Cancer research 20030615

Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.

Rheumatology (Oxford, England) 20030601

Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens.

Bone 20030601

Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis.

International journal of clinical practice 20030601

Effects of ibandronate on inflammation in mouse antigen-induced arthritis.

Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20030501

The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.

Bone 20030401

Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate.

Alimentary pharmacology & therapeutics 20030315

Review of ibandronate in the treatment of osteoporosis.

Expert opinion on pharmacotherapy 20030301

Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20030201

Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys.

Bone 20030101

Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.

European journal of haematology 20030101

Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.

Clinical therapeutics 20030101

Bisphosphonates in the management of metastatic prostate cancer.

Oncology 20030101

[Effects of ibandronate on the osteopenia process in tail-suspended rats].

Aviakosmicheskaia i ekologicheskaia meditsina = Aerospace and environmental medicine 20030101

Treatment of hypercalcemia of malignancy with bisphosphonates.

Seminars in oncology 20021201

Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

Cancer research 20021115

The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption.

Calcified tissue international 20021001

The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.

Breast cancer research and treatment 20021001

Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats.

The Journal of rheumatology 20021001

Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation.

Transplantation proceedings 20020901

Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020701

Novel therapeutic options for osteoporosis.

Current opinion in rheumatology 20020701

Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products.

Annals of the rheumatic diseases 20020601

Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts.

Journal of endocrinological investigation 20020601

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020501

Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats.

The Journal of rheumatology 20020501

Bisphosphonates for prevention of postmenopausal osteoporosis.

Danish medical bulletin 20020201

Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat.

Bone 20020101

Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis.

Bone 20020101

Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastasis following rapid infusion.

In vivo (Athens, Greece) 20020101

Ibandronate in the treatment of prostate cancer associated painful osseous metastases.

Prostate cancer and prostatic diseases 20020101

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20011001

[Radiotherapy and bisphosphonate therapy in bone metastases of prostate carcinoma].

Praxis 20010920

Effect of ibandronate on bone loss and renal function after kidney transplantation.

Journal of the American Society of Nephrology : JASN 20010701

The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.

Cancer research 20010601

Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption.

Arteriosclerosis, thrombosis, and vascular biology 20010501

Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma.

Experimental hematology 20010401

Bisphosphonates induce breast cancer cell death in vitro.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20001101

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 19980401